loader2
Partner With Us NRI

Company details

270.00
296.90
270.00
539.80
6M Return -18.27%
1Y Return -18.24%
Mkt Cap.(Cr) 220.92
Volume 4,416
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 4,416

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 170.47 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 28,019.57 -43,282.61
LAST 3M 77,901.94 -49,701.23
LAST 6M 142,324.16 -198,923.20
LAST 12M 202,461.29 -168,761.49
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Aug 17, 2021 Dividend 30

Information

  • About Company
  • Company Info
  • Listing Info
0
63.88%
201.2081
-8.15%
-18.02%
Description
  • Dai Ichi Karkaria (DIK), manufactures speciality chemicals has a tie-up with Matsumoto to manufacture spin finishes, which are used for imparting lubrication and anti-static properties to textile filaments and yarns. It is now expanding its production capacity from 750 tpa to 3000 tpa. DIK had set up a unit to manufacture certain bulk drugs omeprazole, menadione and calcium pentothenate, the last two will be manufactured in India for the first time. DIK is also setting up a unit to manufacture 600 tpa of polyacrylamide-based flocculents which are used for solid-liquid separation. The expansion cum Diversification plan for High Molecular Weight Flocculants Project at Kurkumbh has been successfully completed. Company had joint venture with project consultant for effluent treatment plants for increasing business. Company Bulk Drugs & Fine Chemical Projects for patented molecule processes were developed and were scaled up to commercial level by March-99. Company plans to start development of three new products in the pilot facility which is being upgraded presently to meet strict cGMP condition. Company also negotiating with foreign customer for product specific tie-ups in future. Company Spin fishes continue to do well & POY DTY finish has been accepted in the market & company hopes to get orders from leading synthetic fibre manufacturers. During the year 1999-2000, the company`s successfully introduced eight new products in therapeutic areas of cardiovascular, antihistaminics, analgesics, anxiolytic, antidepressant and anticonsulgants. The diversification programme which was taken up by the company is focusing in the three major areas are ETP,paper and Alumina industry.

Read More

Registered Address

Liberty Cinema Building, Sir Vithaldas Thackersey Marg, Mumbai, Maharashtra, 400020

Tel : 91-022-22017130/22015895
Email : investor:dai-ichiindia.com
Website : http://www.dai-ichiindia.com

Registrar

Sharex Dynamic (India) Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 526821
NSE Code : DAICHIKARK
Book Closure Date (Month) : Aug
BSE Group : X
ISIN : INE928C01010

ICICIdirect Dai-ichi Karkaria Ltd FAQ

You can buy Dai-ichi Karkaria Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dai-ichi Karkaria Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 18, 2022 04:01 PM the closing price of Dai-ichi Karkaria Ltd was ₹ 296.50.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 18, 2022 04:01 PM, the market cap of Dai-ichi Karkaria Ltd stood at ₹ 220.92.
The latest PE ratio of Dai-ichi Karkaria Ltd as of May 18, 2022 04:01 PM is 0
The latest PB ratio of Dai-ichi Karkaria Ltd as of May 18, 2022 04:01 PM is 0.68
The 52-week high of Dai-ichi Karkaria Ltd is ₹ 539.80 while the 52-week low is ₹ 270.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE